| Criteria | WHO (1998, 1999) | EGIR (1999) | NCEP ATP III (2001, 2004) | AACE/ACE (2003) | IDF (2005) | IDF & AHA/NHLBI (2009) | 
| Required factor | IGT, IFG or DM type 2, and/or insulin resistance | Insulin resistance or hyperinsulinemia | None | At least one of the specified risk  factors (e.g., obesity,
sedentary lifestyle, age>40) | Central obesity | None | 
|  | plus any 2 or more of the following | plus any 2 of the following | but any 3 or more of the following | plus 2 or more of the following | plus any 2 of the following | but any 3 or more of the following | 
| Additional factors | 
| Obesity | Waist-to-hip ratio | WC≥94 cm (men) | WC≥102 cm (men) | BMI>25 kg/m² or |  | Elevated WC and | 
|  | >0.90 (men) | WC≥80 cm (women) | WC≥88 cm (women) | WC>102 cm (men) |  | country-specific | 
|  | Waist-to-hip ratio |  |  | WC>89 cm (women) |  | definitions as | 
|  | >0.85 (women) |  |  | (10-15% lower for |  | defined by the | 
|  | and/or BMI |  |  | non-Caucasians) |  | IDF and | 
|  | >30 kg/m² |  |  |  |  | AHA/NHLBI | 
|  |  |  |  |  |  | until more data | 
|  |  |  |  |  |  | are available | 
| Triglycerides | ≥150 mg/dL | >177 mg/dL | ≥150 mg/dL | >150 mg/dL | ≥150 mg/dL | ≥150 mg/dL | 
|  | (≥1.7 mmol/L) | (>2.0 mmol/L) | (≥1.7 mmol/L) |  | (≥1.7 mmol/L) | (≥1.7 mmol/L) | 
|  |  |  | or on elevated |  | or on lipid | (Rx for elevated | 
|  | and/or |  | triglycerides Rx |  | abnormality Rx | triglycerides is an | 
|  |  |  |  |  |  | alternate indicator) | 
| HDL - | <35 mg/dL | <40 mg/dL | <40 mg/dL | <40 mg/dL (men) | < 40 mg/dL | <40 mg/dL | 
| cholesterol | (<0.9 mmol/L) (men) | (<1.0 mmol/L) | (<1.03 mmol/L) (men) | <50 mg/dL (women) | (<1.03 mmol/L) | (<1.0 mmol/L) | 
|  | <39 mg/dL | (men and women) | <50 mg/dL (<1.29 |  | (men) | (men) <50 mg/dL | 
|  | (<1.0 mmol/L) | or on dyslipidemia Rx | mmol/L) (women) or |  | <50 mg/dL | (<1.3 mmol/L) | 
|  | (women) |  | on reduced |  | (<1.29 mmol/L) | (women) (Rx for | 
|  |  |  | HDL-cholesterol Rx |  | (women) | reduced | 
|  |  |  |  |  | or on lipid | HDL-cholesterol | 
|  |  |  |  |  | abnormality Rx | is an alternate | 
|  |  |  |  |  |  | indicator) | 
| Blood | ≥160/90 mm Hg | ≥140/90 mm Hg or | ≥130/85 mm Hg or | >130/85 mm Hg | ≥130/85 mm Hg | ≥130/85 mm Hg | 
| pressure | (later modified as | on hypertension Rx | on hypertension Rx |  | or on | (antihypertensive | 
|  | ≥140/90 mm Hg) |  |  |  | antihypertensive Rx | Rx in a patient with | 
|  |  |  |  |  |  | a history of | 
|  |  |  |  |  |  | hypertension is an | 
|  |  |  |  |  |  | alternate indicator) | 
| Glucose | IGT, IGF | IGT or IFG | ≥110 mg/dL | 110-125 mg/dl | ≥100 mg/dL | ≥100 mg/dL | 
|  | (≥110 mg/dL) | (≥110 mg/dL) | (≥6.1 mmol/L) |  | (≥5.6 mmol/L) | (≥5.6 mmol/L) | 
|  | (≥6.1 mmol/L), | (≥6.1 mmol/L) | (includes DM) |  | or previously | (Rx of elevated | 
|  | or DM type 2 | (but not DM) | (later modified as |  | diagnosed type | glucose is an | 
|  |  |  | ≥100 mg/dL) |  | 2 DM | alternate indicator) | 
|  |  |  | (≥5.6 mmol/L) or on |  |  |  | 
|  |  |  | elevated glucose Rx |  |  |  | 
| Other | Microalbuminuria |  |  |  |  |  | 
|  | (urinary albumin |  |  |  |  |  | 
|  | excretion rate |  |  |  |  |  | 
|  | ≥20 μg/min or |  |  |  |  |  | 
|  | albumin: creatinine |  |  |  |  |  | 
|  | ratio ≥20 mg/g) (later |  |  |  |  |  | 
|  | modified as ≥30 |  |  |  |  |  | 
|  | mg/g) |  |  |  |  |  | 
| WHO: World Health Organization; EGIR: European Group for the
Study of Insulin Resistance; NCEP ATP III: National Cholesterol Education
Program Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III); AACE/ACE: American Association
of Clinical Endocrinologists/American College of Endocrinology; IDF: International
Diabetes Federation; AHA/NHLBI: American Heart Association/National Heart,
Lung, and Blood Institute; IGT: impaired glucose tolerance; IFG: impaired
fasting glucose; DM: diabetes mellitus; BMI: body mass index; WC: waist circumference;
Rx: treatment; HDL: high-density lipoprotein. |